Emd Serono, INC.
Client is a biopharmaceutical company.
Based in MA
🤖
AI Overview
With $1.6M in lobbying spend across 31 quarterly filings, Emd Serono, INC. is a significant lobbying presence.
$1.6M
Total Lobbying Spend
31
Quarterly Filings
1
Lobbying Firms Used
7
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $200K |
| 2019 | $200K |
| 2020 | $200K |
| 2021 | $150K |
| 2022 | $200K |
| 2023 | $200K |
| 2024 | $200K |
| 2025 | $200K |
Lobbying Firms
THE MCMANUS GROUP
What They Lobby For
- General pharmaceutical coverage and reimbursement issues, health exchange policy; issues and activities affecting oncology, neurodegenerative and fertility products.
- Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products.
- Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Part D reimbursement reform.
- Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Part D reimbursement reform. H.R. 2113, the Prescription Drug STAR Act.
- Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Part D reimbursement reform in H.R. 3, the Lower Drug Costs Now Act, and S. 2543, the Prescription Pricing Reduction Act.
- Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Part D reimbursement reform in S. 2543, the Prescription Drug Pricing Reduction Act of 2019, H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19/ S. 3129, the Lower Costs, More Cures Act of 2019.
- Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Part D reimbursement reform in S. 2543 and H.R. 19/ S. 3129, the Lower Costs, More Cures Act of 2019.
- General pharmaceutical coverage and reimbursement issues, issues and activities affecting oncology, neurodegenerative and fertility products.
- Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Provisions included in Subtitle J - Drug Pricing of H.R. 5376 - Build Back Better Act.
- Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Provisions included in Subtitle J of H.R. 5376 - Build Back Better Act.
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.